TELA Jumps 16.7%, MNTK 14.3% as EPS Estimates Get Revised Up
Small-cap and micro-cap names dominated today's EPS-revision leaderboard, with TELA Bio up 16.7% to $0.91 and Montauk Renewables up 14.3% to $2.55 since detection. Amber International rose 11.0% after its Q2 2026 print showed 38.8% sequential revenue growth and a swing to positive operating income. Marvell Technology added 9.9% to $226.96 as Wall Street's AI-infrastructure optimism reinforced its 60.1% next-year EPS growth estimate.
| Ticker | Sector | Detected | EPS Revision | Gain Since Detection |
|---|---|---|---|---|
| TELA | Healthcare | 2026-09-03 | +8.4pp | +16.7% |
| MNTK | Basic Materials | 2026-09-04 | +5.3pp | +14.3% |
| PMVP | Healthcare | 2026-09-04 | N/A | +11.6% |
| AMBR | Financial | 2026-09-04 | N/A | +11.0% |
| MRVL | Technology | 2026-09-02 | N/A | +9.9% |
Why did TELA stock jump in September 2026?
TELA Bio jumped 16.7% to $0.91 from $0.78 after its next-year EPS growth estimate was revised to 34.2% from 25.8% on September 3, 2026.
The +8.4 percentage-point revision represented a 33% relative upgrade to the forward earnings-growth outlook for the surgical reconstruction device maker. No company-specific earnings headlines hit the tape during the window, which points to the screener catching the estimate move before the broader market repriced the micro-cap name. The move also fits a broader bid for small-cap healthcare medtech stories, where modest revenue beat-and-raise setups can drive outsized percentage moves on thin float.
TELA EPS revision history → · Screener snapshot from 2026-09-03 →
FAQ: TELA
Why did TELA stock jump?
TELA Bio rose 16.7% to $0.91 after its next-year EPS growth estimate was revised up to 34.2% from 25.8% on September 3, 2026, a +8.4 percentage-point revision.
What is TELA's EPS growth estimate?
TELA's next-year EPS growth estimate stands at 34.2%, up from 25.8% prior to the September 3, 2026 revision.
Is TELA a buy after the rally?
TELA has already gained 16.7% since the EPS revision was detected at $0.78, leaving the shares at $0.91 where valuation and liquidity risk are elevated for a micro-cap with no fresh earnings news to confirm the estimate move.
Why did MNTK stock jump in September 2026?
MNTK climbed 14.3% to $2.55 from $2.23 after analysts lifted its next-year EPS growth estimate to 40.6% from 35.3% on September 4, 2026.
The +5.3 percentage-point revision to the renewable natural gas producer's forward earnings outlook arrived without any accompanying earnings-related news release. Basic Materials names tied to RNG and landfill-gas-to-energy have benefited from firmer environmental credit pricing and steady utility-contracted volumes, supporting the improved earnings trajectory. The price move suggests the market gradually validated the estimate revision within a week of the screener flagging it, consistent with the pattern of small-cap revisions pricing in over multiple sessions.
MNTK EPS revision history → · Screener snapshot from 2026-09-04 →
FAQ: MNTK
Why did MNTK stock rise recently?
Montauk Renewables gained 14.3% to $2.55 after its next-year EPS growth estimate was revised up to 40.6% from 35.3% on September 4, 2026.
What is MNTK's EPS growth estimate?
MNTK's next-year EPS growth estimate is 40.6%, up from 35.3% prior to the revision detected on September 4, 2026.
Is MNTK a buy after the 14% rally?
MNTK has appreciated 14.3% since the estimate revision at $2.23, and with no fresh earnings news to confirm the upgrade, the risk-reward has shifted for investors who did not participate at detection.
Why did PMVP stock jump in September 2026?
PMVP gained 11.6% to $1.44 from $1.29 after the EPS screener detected a 25.1% next-year growth estimate on September 4, 2026.
PMV Pharmaceuticals, a precision oncology developer, carried no earnings-related headlines during the measurement window, so the move is best explained by estimate-driven screen flows into small-cap Healthcare. The company's p53-targeted cancer programs sit in a therapeutic class where partnership and data-readout speculation periodically compresses into sharp micro-cap moves. With the stock trading under $1.50, the 11.6% gain reflects relatively modest dollar volume — the profile of an early-stage name that re-rates quickly on any positive estimate signal.
PMVP EPS revision history → · Screener snapshot from 2026-09-04 →
FAQ: PMVP
Why did PMVP stock rise 11%?
PMV Pharmaceuticals rose 11.6% to $1.44 from $1.29 after a 25.1% next-year EPS growth estimate was detected by the screener on September 4, 2026.
What is PMVP's EPS growth estimate?
PMVP's next-year EPS growth estimate is 25.1%, as flagged by the EPS revision screener on September 4, 2026.
Is PMVP a buy after the gain?
PMVP's 11.6% move was not accompanied by any earnings-related news, so the advance rests on estimate-driven screen flows rather than a confirmed fundamental catalyst — a higher-risk setup for momentum buyers.
Why did AMBR stock jump in September 2026?
AMBR surged 11.0% to $1.01 from $0.91 following its September 3, 2026 Q2 print that showed revenue up 38.8% sequentially and operating income swinging to positive $1 million.
The earnings call disclosed the company's pivot from digital wealth management to specialized AI agents, with gross margin expanding to 79.5% and adjusted EBITDA turning positive at $1.9 million. That operational inflection supports the 200.0% next-year EPS growth estimate on the screen, which is effectively a swing from a loss-making base to profitability. Management also repurchased roughly 2.6 million ADSs for about $5.8 million, tightening the share count as the AI-agent pivot accelerates.
AMBR EPS revision history → · Screener snapshot from 2026-09-04 →
FAQ: AMBR
What caused AMBR's 11% surge?
Amber International's Q2 2026 results reported September 3, 2026 showed revenue up 38.8% sequentially to $13.9 million, gross margin at 79.5%, and a swing to $1 million in operating income and $1.9 million in adjusted EBITDA.
What is AMBR's EPS growth estimate?
AMBR's next-year EPS growth estimate is 200.0%, reflecting the swing from prior losses to profitability reported in Q2 2026.
Is AMBR a buy after the AI agent pivot?
AMBR's Q2 2026 showed $34.2 million in cash, a $5.8 million buyback of ~2.6 million ADSs, and its first quarter of AMM/agentic revenue at $3.5 million, but the 200.0% EPS growth estimate is off a loss base and hinges on the AI agent strategy scaling.
Why did MRVL stock jump in September 2026?
MRVL added 9.9% to $226.96 from $206.48 as analysts held a 60.1% next-year EPS growth estimate that was detected on September 2, 2026.
The estimate sits on top of Marvell's raised fiscal 2028 revenue outlook of approximately $18 billion — up $1.5 billion in a single quarter — with management guiding its data center segment to grow more than 60% in fiscal 2028. Custom XPU silicon for hyperscalers is the primary driver, though management cautioned non-GAAP gross margin will compress to a 57.5%–58.5% range as that mix ramps. Continued analyst coverage comparing Marvell's cost-per-dollar-of-profit to NVIDIA kept the AI-infrastructure trade in focus through the run, reinforcing the price advance.
MRVL EPS revision history → · Screener snapshot from 2026-09-02 →
FAQ: MRVL
Why did MRVL stock jump 9.9%?
Marvell Technology rose 9.9% to $226.96 from $206.48 as its 60.1% next-year EPS growth estimate, detected September 2, 2026, was reinforced by a raised fiscal 2028 revenue outlook of approximately $18 billion.
What is MRVL's EPS growth estimate?
MRVL's next-year EPS growth estimate is 60.1%, anchored by management's guidance for data center revenue growth above 60% in fiscal 2028.
Is MRVL a buy after the AI data center rally?
MRVL has gained 9.9% since detection at $206.48, and while fiscal 2028 revenue guidance of ~$18 billion and 60%+ data center growth support the thesis, gross margin is guided down to 57.5%–58.5% as custom XPU silicon ramps.
Today's leaders skew heavily to micro- and small-cap names, signaling that EPS-revision screens are finding early repricing opportunities in Healthcare and Basic Materials before they reach mainstream coverage. Amber International's Q2 print stands out as the only confirmed fundamental catalyst in the group, validating that estimate revisions backed by reported results carry more durable price follow-through than screen-only signals.
How We Identify These Stocks
We track daily changes in forward EPS estimates across thousands of US equities. When a stock's next-year earnings growth estimate is revised upward — confirmed by improvement in current-year estimates — it enters our watchlist. The stocks above were flagged on their detection dates and have since delivered the strongest price returns among all detected stocks.
Explore today's full screener →